Galatea Bio

Executive Summary

Galatea Bio is a San Francisco-based biotechnology company leveraging AI and machine learning to advance genomic analysis for drug discovery and precision medicine. Founded in 2021, the company develops platforms that extract actionable insights from complex genomic data, aiming to accelerate the identification of novel drug targets and enable personalized therapies. By combining large-scale genomic datasets with proprietary algorithms, Galatea Bio addresses critical bottlenecks in translating genetic discoveries into clinical applications. While the company remains private with no disclosed funding rounds or valuation, its focus on AI-driven genomics positions it within a rapidly growing sector that has attracted significant investor interest. The company's early-stage status suggests potential for partnerships or funding events that could catalyze its trajectory.

Upcoming Catalysts (preview)

• Q3 2026Series A Funding Round70% success
• Q2 2026Pharma Partnership Announcement60% success
• Q4 2026Platform Launch or Major Dataset Release50% success